Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.

Read narrative

SciSparc Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for SciSparc
Historical stock prices
Current Share Price	US$6.72
52 Week High	US$80.10
52 Week Low	US$2.98
Beta	2.4
1 Month Change	102.41%
3 Month Change	9.16%
1 Year Change	-89.84%
3 Year Change	-99.78%
5 Year Change	n/a
Change since IPO	-99.90%

Recent updates

Seeking Alpha • Aug 15

SciSparc to acquire an American food supplements and cosmetics brand in ~$20M deal

A specialty clinical-stage pharmaceutical company SciSparc (NASDAQ:SPRC) signed a letter of intent with Merhavit M.R.M Holding and Management to acquire from it its rights to purchase, a top-seller Amazon.com account and American food supplements and cosmetics brand and trademark (Brand). The Brand offers dozens of GMP (Good Manufacturing Practice) manufactured hemp-based, U.S. made, top-ranked products, including various food supplements for different purposes and cosmetics. Company will pay a base payment of $4.59M upon closing of the transaction and an additional deferred cash payment of up to $1.1M that will be based on a multiple of 12 months EBITDA of the acquired Brand. “Our decision to enter this LOI is part of a previous board of directors decision to search for strategic transactions in high growth, high potential markets. We believe that acquiring a profitable top-seller brand with millions of dollars in annual sales, combined with our knowledge and expertise, can provide value to our shareholders. This potential transaction will expand our access to manufacturing and distribution channels, which aligns with our intention to market CannaMideTM, our PEA- based food supplement.“ commented Oz Adler, CEO.

Seeking Alpha • Jul 06

SciSparc board of directors to promote buyback program of up to $1M

SciSparc (NASDAQ:SPRC) authorized the company to take actions to implement a $1M buyback program for the company’s ordinary shares. The company expects to formally approve the buyback in conjunction with the approval of its financial statements for the 6 months ended June 30, 2022, together with a financial advisor’s opinion to be obtained.

Seeking Alpha • Jun 29

SciSparc completes development of SCI-110 to treat tourette syndrome

SciSparc (NASDAQ:SPRC) said on Wednesday it completed the development of its drug candidate, SCI-110, for Phase IIb study to treat tourette syndrome. SCI-110 is developed and manufactured by Procaps Group S.A. Tourette syndrome is a movement and neurobehavioral disorder characterized by chronic motor and vocal tics. The main goal of the study is to assess tic severity change as a continuous endpoint at week 12 and week 26.

Shareholder Returns

	SPRC	US Pharmaceuticals	US Market
7D	-23.4%	-1.9%	2.1%
1Y	-89.8%	33.3%	30.6%

Return vs Industry: SPRC underperformed the US Pharmaceuticals industry which returned 33.4% over the past year.

Return vs Market: SPRC underperformed the US Market which returned 31% over the past year.

Price Volatility

Is SPRC's price volatile compared to industry and market?
SPRC volatility
SPRC Average Weekly Movement	22.9%
Pharmaceuticals Industry Average Movement	9.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.1%
10% least volatile stocks in US Market	3.2%

Stable Share Price: SPRC's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SPRC's weekly volatility has decreased from 29% to 23% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2004	2	Oz Adler	scisparc.com

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others.

SciSparc Ltd. Fundamentals Summary

How do SciSparc's earnings and revenue compare to its market cap?
SPRC fundamental statistics
Market cap	US$3.61m
Earnings (TTM)	-US$12.18m
Revenue (TTM)	US$856.00k

4.4x

P/S Ratio

-0.3x

P/E Ratio

Is SPRC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SPRC income statement (TTM)
Revenue	US$856.00k
Cost of Revenue	US$225.00k
Gross Profit	US$631.00k
Other Expenses	US$12.81m
Earnings	-US$12.18m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-21.54
Gross Margin	73.72%
Net Profit Margin	-1,422.78%
Debt/Equity Ratio	6.9%

How did SPRC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/07 17:02
End of Day Share Price	2026/05/07 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SciSparc Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Nathan Weinstein	Aegis Capital Corporation
Piriyapon Kongvanich	Bualuang Securities PCL
Maxim Jacobs	Edison Investment Research

SciSparc (SPRC) Stock Overview

Risk Analysis

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

SciSparc Ltd. Competitors

Numinus Wellness

China SXT Pharmaceuticals

Universe Pharmaceuticals

Gelteq

Price History & Performance

Recent News & Updates

Full year 2025 earnings released: EPS: US$98.07 (vs US$204 loss in FY 2024)

New major risk - Share price stability

CliniQuantum Ltd. entered into a definitive share purchase agreement to acquire Neurothera Labs Inc. (TSXV:NTLX) from SciSparc Ltd. (NasdaqCM:SPRC) in a reverse merger transaction.

SciSparc Ltd. announced that it expects to receive $9 million in funding from L.I.A. Pure Capital Ltd.

SciSparc Ltd. has filed a Follow-on Equity Offering in the amount of $0.76617 million.

SciSparc Ltd. has filed a Follow-on Equity Offering in the amount of $2.261975 million.

Recent updates

Full year 2025 earnings released: EPS: US$98.07 (vs US$204 loss in FY 2024)

New major risk - Share price stability

CliniQuantum Ltd. entered into a definitive share purchase agreement to acquire Neurothera Labs Inc. (TSXV:NTLX) from SciSparc Ltd. (NasdaqCM:SPRC) in a reverse merger transaction.

SciSparc Ltd. announced that it expects to receive $9 million in funding from L.I.A. Pure Capital Ltd.

SciSparc Ltd. has filed a Follow-on Equity Offering in the amount of $0.76617 million.

SciSparc Ltd. has filed a Follow-on Equity Offering in the amount of $2.261975 million.

New major risk - Negative shareholders equity

New minor risk - Financial data availability

SciSparc Ltd. Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Scisparc Ltd. Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize Ai Drug Discovery

SciSparc -Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

SciSparc Regains Compliance with Nasdaq Minimum Bid Price Notification

SciSparc Ltd. Announces Publication of Japanese Patent Application

SciSparc Ltd., Annual General Meeting, Jun 25, 2025

SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

Full year 2024 earnings released: US$1.28 loss per share (vs US$12.55 loss in FY 2023)

Scisparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and Other Eating Disorders

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

N2OFF, Inc. (NasdaqCM:NITO) entered into a Securities Purchase and Exchange Agreement to acquire MitoCareX Bio Ltd from SciSparc Ltd. (NasdaqCM:SPRC), Alon Silberman and Ciro Leonardo Pierri.

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

New major risk - Share price stability

New minor risk - Financial data availability

An undisclosed buyer signed a letter of intent to acquire 52.73% stake in MitoCareX Bio Ltd from SciSparc Ltd. (NasdaqCM:SPRC).

SciSparc Takes Major Step Forward with IND Application Submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc -Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

SciSparc Ltd. Submits IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome

SciSparc Ltd., Annual General Meeting, Oct 01, 2024

SciSparc Ltd Announces Enrollment of the First Five Patients in the Clinical Trial of Its Innovative Sci-210 Treatment

New minor risk - Share price stability

SciSparc Ltd. (NasdaqCM:SPRC) signed a merger agreement to acquire remaining stake in Automax Motors Ltd (TASE:AMX).

SciSparc Ltd. Announces Successfully Dosed the First Patient in Its SCI-210 Clinical Trial At the Soroka Medical Center for Pediatric Patients

Investor sentiment deteriorates as stock falls 16%

SciSparc Ltd. Announces Enrollment of First Patient for Its Clinical Trial for Children with Autism Spectrum Disorder

Scisparc Ltd. Granted Patent for Core Technology in Multiple Jurisdictions in Europe

Investor sentiment improves as stock rises 17%

Insufficient new directors

Scisparc Ltd. Announces Initiation of Patient Recruitment for Its Clinical Trial with Sci-210 in Children with Autism Spectrum Disorder

Investor sentiment improves as stock rises 68%

SciSparc Ltd. announced that it expects to receive $20 million in funding from Yorkville Advisors Global LP

Investor sentiment deteriorates as stock falls 18%

Scisparc Ltd. and Clearmind Medicine Inc. Announces Obesity Drug Showed Positive Results in A Pre-Clinical Trial

SciSparc Ltd. Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment

SciSparc Ltd. Announces Initiation of its Phase IIb Clinical Trial Treatments with its SCI-110, Proprietary Drug Candidate

SciSparc Ltd. Receives Patent from the Australian Patent Office for Its Reduction of Opioids Use in Pain Management Technology

SciSparc Ltd. Receives Notice of Acceptance for Its Core Technology Application for the Combinations of Cannabinoids and N-Acylethanolamines

Investor sentiment improves as stock rises 85%

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

SciSparc Ltd. announced that it expects to receive $5.018281 million in funding

SciSparc Ltd. Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Continues to Increase Its Patent Portfolio in the Field of Movement Abnormalities in the U.S

SciSparc Ltd., Annual General Meeting, Aug 15, 2023

SciSparc Ltd. Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany

Scisparc Ltd. Announces Irb Approval to Conduct Its Phase Iib Trial in Tourette Syndrome

New major risk - Share price stability

Capital Point Ltd. Files Suit Against SciSparc Ltd

SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center

SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment

SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center

SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial

Scisparc Announces Positive Study Results with Sci-210, A Cannabidiol-Based Treatment for Epilepsy

SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

SciSparc Ltd. Announces Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation